Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ≥6 Years with Cystic Fibrosis and At Least One F508del Allele: A Phase 3, Open-Label Clinical Trial.
Claire WainwrightSusanna A McColleyPaul McNallyMichael PowersFelix RatjenJonathan H RaymentGeorge Retsch-BogartErica RoeschNeil AhluwaliaAnna ChinChenghao ChuMengdi LuPrema MenonDavid WaltzTanya WeinstockLaura ZelazoskiJane C Daviesnull nullPublished in: American journal of respiratory and critical care medicine (2023)
gov, ID: NCT04183790.